Elisabet Manasanch is an Oncology physician affiliated with GlaxoSmithKline. OpenAlex indexes 290 publications with 4,013 citations (h-index 26); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 28 May 2014.
Clinical trials
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
- Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
Sponsor: JW Pharmaceutical
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Adaptive Biotechnologies CorporationProgram year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20232 payments
- PFIZER INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.3%Thalidomide Analog62.3%Revlimid45%Lenalidomide36%Pomalyst18%Part D≥33 patientsAnti-infectives
24.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.2%Valacyclovir100%Part D≥25 patientsFluoroquinolone Antibacterial4.5%Levofloxacin100%Part D≥12 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.5%Proton pump inhibitor6.5%Pantoprazole Sodium100%Part D≥13 patientsSerotonin-3 Receptor Antagonist3%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”